Summarized by Masters of Longevity from Longevity Technology.
Phase 1 studies reported safety and preliminary weight‑loss effects for ATX‑304.

Key Takeaways
- Cambrian Bio reported Phase 1 safety and early weight loss.
- ATX‑304 Phase 1 results were generally tolerable in participants.
- Early signals from ATX‑304 support advancing to larger trials.



